# Can ARA-290 reduce inflammation in aging-related intestinal conditions?

Canonical source: https://retacompare.com/research/can-ara-290-reduce-inflammation-in-aging-related-intestinal-conditions

Peptide Longevity Q&A · 2017-10-12


    Research indicates that ARA-290, also known as cibinetide, demonstrates significant anti-inflammatory effects in experimental colitis, potentially improving tissue integrity and reducing disease activity, which may have implications for aging-related inflammatory conditions in the gut.

 What the research shows

The study investigated the effects of ARA-290 (cibinetide) on experimental colitis induced by dextran sulphate sodium (DSS) in C57BL/6N mice. The research aimed to assess the therapeutic potential of cibinetide in ameliorating the clinical course of colitis. Mice subjected to colitis were treated with either solvent, erythropoietin (EPO), or cibinetide. The outcomes measured included weight gain, survival rates, and tissue integrity, along with the infiltration of myeloid cells and the production of pro-inflammatory mediators such as cytokines and nitric oxide synthase-2. The findings demonstrated that both cibinetide and EPO improved clinical outcomes in the colitis model, highlighting the potential of cibinetide in reducing inflammation.

 Why it matters for longevity

Chronic inflammation is a significant contributor to various age-related diseases, including inflammatory bowel disease (IBD). The findings from this research suggest that ARA-290 may play a role in mitigating inflammation associated with aging-related intestinal conditions. By reducing the infiltration of myeloid cells and the production of inflammatory mediators, cibinetide could potentially enhance gut health and overall well-being in aging populations. The preservation of tissue integrity and reduction of disease activity may contribute to a healthier lifespan, emphasizing the importance of targeting inflammation in aging research. Understanding the mechanisms through which ARA-290 operates could pave the way for new therapeutic strategies aimed at improving healthspan in older adults.

 Key findings at a glance

ARA-290 (cibinetide) improved clinical outcomes in a mouse model of colitis.

Treated mice showed enhanced weight gain and survival rates.

Cibinetide reduced infiltration of myeloid cells in inflamed tissues.

It diminished the production of pro-inflammatory mediators, including cytokines.

The anti-inflammatory effects were linked to the activity of the innate repair receptor (IRR).

 How ARA-290 works (background)

ARA-290 functions as a selective agonist of the innate repair receptor (IRR), which is formed by the interaction of the erythropoietin receptor (EPOR) and the β-common receptor (CD131). This receptor complex exerts tissue protective effects, particularly in immune cells. The activation of IRR by cibinetide leads to the inhibition of NF-κB subunit p65 activity, a key regulator of inflammation. By modulating the inflammatory response, ARA-290 can help preserve tissue integrity and reduce the severity of inflammatory conditions, making it a candidate for further exploration in the context of aging-related diseases.

 Safety, caveats, and what we don't yet know

While the research demonstrates promising results regarding the anti-inflammatory effects of ARA-290 in a preclinical model of colitis, it is essential to note that these findings are not yet confirmed in human populations. The study was conducted in mice, and further research is needed to evaluate the safety and efficacy of cibinetide in aging individuals or those with chronic inflammatory conditions. Additionally, the long-term effects of ARA-290 treatment and its potential interactions with other therapies remain to be explored. Understanding these factors will be crucial in determining the clinical utility of ARA-290 for aging-related inflammatory diseases.

 Bottom line

The research indicates that ARA-290 may reduce inflammation and improve outcomes in experimental colitis, suggesting potential benefits for aging-related inflammatory conditions. However, further studies are needed to validate these findings in humans.

 Related questions

 Can ARA-290 improve gut health in older adults?

Research suggests that ARA-290 may enhance gut health by reducing inflammation, which is crucial in aging populations vulnerable to inflammatory bowel diseases.

 Does ARA-290 have potential in treating age-related diseases?

Yes, ARA-290's anti-inflammatory properties may offer therapeutic potential for various age-related diseases characterized by chronic inflammation.

 What are the implications of ARA-290 for inflammatory bowel disease?

ARA-290 shows promise as a disease-modifying therapeutic for inflammatory bowel disease, potentially improving clinical outcomes and quality of life.

 Source: PubMed · Sci Rep · published 2017-10-12.

## Sources

- PubMed · Sci Rep: https://pubmed.ncbi.nlm.nih.gov/29026145/